August 15, 2009
BioMedReports.com’s Mike Havrilla recently posted a new article and 19-page report on Access Pharmaceuticals, Inc. following the filing of the Company’s quarterly report on August 13, 2009 and Havrilla’s recent Q&A with the Company’s President and CEO, Jeffrey B. Davis.
The report features information on:
• Key financial metrics
• Near, intermediate and long-term catalysts for growth
• Post-marketing study results for MuGard
• North American commercialization strategy for MuGard
• MuGard launch in Asia
• Licensing discussions for Cobalamin
• Prolindac & Thiarabine clinical development
Havrilla’s report projects positive operating cash flow by mid-2010 or earlier depending on MuGard sales, post-marketing study results, and clinical experience. However, my earnings model does not even account for expected upfront licensing and clinical milestone payments for the Company’s cobalamin drug delivery technology, thiarabine, ProLindac, or earlier stage compounds, which have the added potential for $100M in licensing deals (upfront + milestone payments and royalties) for oral basal insulin product, oral hGH, ProLindac, and thiarabine within the next 12-18 months (with $20-30M possible in upfront payments from such deals).
This report contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access’ plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Tweet
Digg!
Del.icio.us
Follow Us
Accesspharma: RT @